Tucatinib/tucatinib efficacy and side effects

Tucatinib/Tucatinib is a targeted anti-cancer drug used in combination with other drugs to treat advanced breast cancer and colorectal cancer. Tucatinib belongs to a class of drugs called tyrosine kinase inhibitors. Tucatinib targetsHER2 (human epidermal growth factor receptor 2) tyrosine kinase. The HER2 receptor is involved in the growth and repair of normal breast cells. But 10 to 20 percent of breast cancers have a faulty HER2 gene that makes too many copies of itself. This causes the HER2 protein to be overexpressed - there are too many HER2 receptors on the breast cells - which allows the breast cells to grow and divide uncontrollably. Tucatinib works by blocking the activity of HER2, which helps slow the growth and spread of cancer cells. It is used in combination with trastuzumab and capecitabine because the combination helps patients live longer without their cancer progressing and live longer overall.

In clinical studies of tucatinib, the most common adverse reactions in patients with metastatic breast cancer were diarrhea, palmoplantar red blood cell paresthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash; the most common adverse reactions in patients with colorectal cancer were diarrhea, fatigue, Rash, nausea, abdominal pain, infusion-related reactions, and fever; the most common laboratory abnormalities were increased creatinine, increased glucose, increased transaminases, decreased hemoglobin, increased bilirubin, increased alkaline phosphatase, lymphopenia, decreased albumin, leukopenia, and sodium decrease.

In general, tucatinib, as a therapeutic drug, has significant efficacy, but it may also cause some side effects. When using tucatinib, patients should pay close attention to their physical condition and communicate with their doctor in a timely manner so that the doctor can adjust the treatment plan according to the actual situation to ensure the patient's safety and therapeutic effect.